Revumenib displayed promising anti-tumor activity among patients with relapsed or refractory KMT2Ar acute leukemia.

Dan Loeb, founder of Third Point, increased his stake in ICE and CRH by over 100% in Q4 2024. This represents a 108.5% increase in share count and a total portfolio value of $334.93 million.

Below is Validea's guru fundamental report for CRH PLC (CRH). Of the 22 guru strategies we follow, CRH rates highest using our Twin Momentum Investor model based on the published strategy of ...

Current price $92.52 52-week high $104.23 ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

CRH plc, a leading player in the building materials industry, announced the acquisition and subsequent cancellation of a significant portion of its ordinary shares as part of a share buyback program.

CRH plc, a leading global building materials company, announced that it has repurchased a number of its ordinary shares through its broker, Mizuho Securities USA LLC, on December 31, 2024.

After hours: January 8 at 7:40:34 p.m. EST ...

CRH plc announced a transaction involving Richard Fearon, a director of the company, who purchased 10,000 ordinary shares at a price of $94.22 per share on December 24, 2024, in New York.